Vaccine Targeted Prophylaxis For Covid-19: A Comprehensive Review
Article Sidebar
-
Covid-19, Coronavirus, Severe Acute Respiratory Syndrome, Vaccine, World Health Organization
Abstract
The Severe acute respiratory syndrome coronavirus-2, the contamination that prompts sickness19(covid-19), has spread quickly from the initially known cases in china in December 2019 to nations round the globe. On March 10,2020, the world health organization reported that there have been 113,702 affirmed instances of corona virus -19 round the globe, additionaly to 4,012 passing. Due to this worldwide well being emergency analysts are handling build up a corona virus immunization. Protected and compelling immunizations are going to be a game changer: yet for years to return we should always wearing covers, genuinely separating and staying faraway from swarms. Being inoculated doesn't imply that we will laugh in the face of any potential risk and put ourselves as well as other people in danger, especially in light of the very fact that it is as yet not satisfactory what proportions the antibodies can ensure against sickness also as against contamination and transmission. Vaccine for corona virus are basic devices for managing the pandemic when joined with compelling testing and existing anticipation measures. The general undertaking to form a secure and effective coronavirus vaccine is proving to be fruitful. A handful of vaccines now are authorized round the globe, may more in development. Antibodies save an excellent many lives per annum.
Full text article
References
Addetia, A., Crawford, K. H. D., Dingens, A., Zhu, H., Roychoudhury, P., Huang, M.-L., Jerome, K. R., Bloom, J. D., Greninger, A. L. 2020. Neutralizing Antibodies Correlate with Protection from SARS-CoV-2 in Humans during a Fishery Vessel Outbreak with a High Attack Rate. Journal of Clinical Microbiology, 58(11):58.
Allotey, B. M., Kew, T. 2020. Clinical manifestations, risk factors, and maternal and perinatal outcomes of corona virus disease 2019 in pregnancy: Living systematic review and meta-analysis. BrMedJ, 370:3320.
Amanat, F., Krammer, F. 2020. SARS-CoV-2 Vaccines: Status Report. Immunity, 52(4):583–589.
Bernal, J., Lopez, Panagiotopoulos, N., Byers, C., Vila- plana, T. G., Boddington, N. L., Zhang, X., Saliba, V. 2020. Transmission dynamics of COVID-19 in household and community settings in the United Kingdom. medRxiv.
Cevik, M., Kuppalli, K., Kindrachuk, J., Peiris, M. 2020. Virology, transmission, and pathogenesis of SARS- CoV-2. BMJ, 371:1–6.
Dhama, K. 2020. Coronavirus disease 2019-COVID-19. Clinical Microbiology Reviews, pages 1–48.
Diggle, L. 2000. Effect of needle length on incidence of local reactions to routine immunisation in infants aged 4 months: randomised controlled trial. BMJ, 321(7266):931–933.
Ecdca 2020. Risk factors and risk groups. European Centre for Disease Prevention and Control, page 3.
Ecdcc 2020. COVID-19 in children and the role of school settings in COVID-19 transmission - first update. European Centre for Disease Prevention and Control.
Elshafeey, F., Magdi, R., Hindi, N., Elshebiny, M., Farrag, N., Mahdy, S., Sabbour, M., Gebril, S., Nasser, M., Kamel, M., Amir, A., Emara, M. M., Nabhan, A. 2020. A systematic scoping review of COVID-19 during pregnancy and childbirth. International Journal of Gynecology and Obstetrics, 150(1):47–52.
Folegatti, P. M., Ewer, K. J., Aley, P. K., Angus, B., Becker, S., Belij-Rammerstorfer, S., Hamlyn, J. 2020. Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial. The Lancet, 396:467–478.
Garofalo, M., Staniszewska, M., Salmaso, S., Caliceti, P., Pancer, K. W., Wieczorek, M., Kuryk, L. 2020. Prospects of Replication-Deficient Adenovirus Based Vaccine Development against SARS-CoV-2. Vaccines, 8:293.
Huang, C., Wang, Y., Li, X., Ren, L., Zhao, J., Hu, Y., Cao, B. 2020. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. The lancet, 395:497–506.
Karimi-Zarchi, M., Neamatzadeh, H., Dastgheib, S. A., Abbasi, H., Mirjalili, S. R., Behforouz, A., Ferdosian, F., Bahrami, R. 2020. Vertical Transmission of Coronavirus Disease 19 (COVID-19) from Infected Pregnant Mothers to Neonates: A Review. Fetal and Pediatric Pathology, 39(3):246–250.
Kaur, S. P., Gupta, V. 2020. COVID-19 Vaccine: A comprehensive status report. Virus research, 198(114).
Kennedy, S. B., Bolay, F., Kieh, M., Grandits, G., Badio, M., Ballou, R., Eckes, R., Feinberg, M., Follmann, D., Grund, B., Gupta, S., Hensley, L., Higgs, E., Janosko, K., Johnson, M., Kateh, F., Logue, J., Marchand, J., Monath, T., Nason, M., Nyenswah, T., Roman, F., Stavale, E., Wolfson, J., Neaton, J. D., Lane, H. C. 2017. Phase 2 Placebo-Controlled Trial of Two Vaccines to Prevent Ebola in Liberia. New England Journal of Medicine, 377(15):1438–1447.
Kroger, A. T., Atkinson, W. L., Pickering, L. A. 2013. General immunization Practices in Plotkin SA, Orenstein WA, Offit PA. pages 15–70, Saunders 2012, Page Count. Elsevier.
Ladhani, S. N., Amin-Chowdhury, Z., Davies, H. G., Aiano, F., Hayden, I., Lacy, J., Sinnathamby, M., de Lusignan, S., Demirjian, A., Whittaker, H., Andrews, N., Zambon, M., Hopkins, S., Ramsay, M. E. 2020. COVID-19 in children: analysis of the first pandemic peak in England. Archives of Disease in Childhood, 105(12):1180–1185.
Lillie, P. J., Samson, A., Li, A., Adams, K., Capstick, R., Barlow, G. D., Easom, N., Hamilton, E., Moss, P. J.,
Evans, A., Ivan, M., Team, P. I., Taha, Y., Duncan, C. J., Schmid, M. L., the Airborne HCID Network 2020. Novel coronavirus disease (Covid-19): The first two patients in the UK with person to person transmission. Journal of Infection, 80(5):578–606.
Mark, A., Carlsson, R. M., Granström, M. 1999. Subcutaneous versus intramuscular injection for booster DT vaccination of adolescents. Vaccine, 17:2067–2072.
Pachetti, M., Marini, B., Giudici, F., Benedetti, F., Angeletti, S., Ciccozzi, M., Masciovecchio, C., Ippodrino, R., Zella, D. 2020. Impact of lockdown on Covid-19 case fatality rate and viral mutations spread in 7 countries in Europe and North America. Journal of Translational Medicine, 18(1):1–7.
Ramasamy, M. N., Minassian, A. M., Ewer, K. J., Flax- man, A. L., Folegatti, P. M., Owens, D. R., Demissie, T. 2020. Safety and immunogenicity of ChAdOx1 nCoV-19 vaccine administered in a prime-boost regimen in young and old adults (COV002): a single-blind, randomised, controlled, phase 2/3 trial. The Lancet, 396:1979–1993.
Sanche, S., Lin, Y. T., Xu, C., Romero-Severson, E., Hengartner, N., Ke, R. 2020. High Contagiousness and Rapid Spread of Severe Acute Respiratory Syndrome Coronavirus 2. Emerging Infectious Diseases, 26:1470–1477.
Thompson, C. P., Grayson, N. E., Paton, R. S., Bolton, J. S., Lourenço, J., Penman, B. S. 2020. Detection of neutralising antibodies to SARS-CoV-2 to determine population exposure in Scottish blood donors between March and May 2020. Eurosurveillance, 25(42):2000685.
Vandoremalen, N., Lambe, T., Spencer, A., Belij-Rammerstorfer, S., Purushotham, J. N., Port, J. R., Munster, V. J. 2020. ChAdOx1 nCoV-19 vaccine prevents SARS-CoV-2 pneumonia in rhesus macaques. Nature, 586(7830):578–582.
Viner, R. M., Mytton, O. T., Bonell, C., Melendez-Torres, G. J., Ward, J. L., Hudson, L. 2020. Susceptibility to and transmission of COVID-19 amongst children and adolescents compared with adults: a systematic review and meta-analysis. medRxiv, pages 20–20108126.
Vogel, A., Kanevsky, I., Che, Y., Swanson, K., Muik, A., Vormehr, M., Sahin, U. 2020. A prefusion SARS-CoV-2 spike RNA vaccine is highly immunogenic and prevents lung infection in non-human primates. BioRxiv.
Walsh, E. E. 2020. RNA-Based COVID-19 Vaccine Pfizer BioNTech COVID-19 vaccine Selected for a Pivotal Efficacy Study. New England Journal of Medicine.
Ward, H., Atchison, C. J., Whitaker, M. 2020. Antibody prevalence for SARS-CoV-2 in England following the first peak of the pandemic: REACT2 study in 100,000 adults. MedRxiv, 1(21).
Waterfield, T., Watson, C., Moore, R., Ferris, K., Tonry, C., Watt, A., Christie, S. 2020. Seroprevalence of SARS-CoV-2 antibodies in children: a prospective multicentre cohort study. Archives of disease in childhood, pages 1–7.
WHO 2020a. Director-General’s opening remarks at the media briefing on COVID-19. [Accessed On: 11 March 2020]. World Health Organization.
WHO 2020b. Novel Coronavirus–China; Emergencies preparedness, response. [Accessed On: 1 Octo- ber 2020]. World Health Organization.
Williamson, E. J., Walker, A. J., Bhaskaran, K., Bacon, S., Bates, C., Morton, C. E., goldacre, B. 2020. Factors associated with COVID-19-related death using OpenSAFELY. Nature, 584(7821):430–436.
Zhu, N., Zhang, D., Wang, W., Li, X., Yang, B., Song, J., Zhao, X., Huang, B., Shi, W., Lu, R., Niu, P., Zhan, F., Ma, X., Wang, D., Xu, W., Wu, G., Gao, G. F., Tan, W. 2019. A Novel Coronavirus from Patients with Pneumonia in China. China Novel Coronavirus Investigating and Research Team, 382:727–733.
Zuckerman, J. N. 2000. The importance of injecting vaccines into muscle. Different sufferers need different needle sizes, 321:1237–1245.
Authors
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.